Infectious Disease & Vaccines

An agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing.

Nonhuman primates treated with the mRNA vaccine recovered faster and had less severe disease than those given available mpox vaccines. 

A new model predicts how well maternal vaccines protect babies from Group B Streptococcus, propelling much needed shots through late-stage clinical trials.

Plectasin forms dense structures on bacterial membranes by binding to unique lipids in bacterial cell walls.

Researchers uncovered the structure of the measles fusion glycoprotein and identified a neutralizing antibody capable of decreasing its virulence.

Biofilms render most antibiotics ineffective, but ultrasound may be the key to clearing these chronic infections.

Placental macrophages play a role in the immune response against pathogens.

Organic molecules with novel biological properties offer new ways to eliminate multidrug-resistant bacteria. 

Cell-free gene synthesis technology offers a quick, reliable route to creating vital mRNA vaccines and therapeutics. 

Zosurabalpin, a macrocyclic peptide, kills drug resistant Acinetobacter baumannii  bacteria by blocking cross-membrane transport.

The durability and capacity to boost protein expression of circular RNA makes it a promising candidate for next-generation vaccines and gene therapies.

Could the solution to antibiotic resistance already have been discovered? Microbiologists and historians probe medieval and ancient texts to find out.